SlideShare una empresa de Scribd logo
1 de 14
4th Annual Scientific Meeting
              Jan 23-25, 2013 Glasgow


Mini Gastric Bypass: initial experience


                    SPIRE Hospital Southampton
                    Department of Bariatric Surgery
                        M Van den Bossche, I Bailey, J Kelly
                                    J Byrne, R Sutherland*



02/02/13                                                       1
Introduction in MGB
   Dr Robert Rutledge
     –   Pioneer
     –   15 year experience
     –   7000 cases
     –   Excellent results
     –   Long term FU




    Mini Gastric Bypass is a
    combination of
         •Collis plasty
         •Billroth 2
Fears and Controversy
 MGB not endorsed by ASMBS or ACS but MGB is clearly on
  the rise throughout the world.
 Fears
    – Cancer
    – Bile reflux
    – Marginal ulcer

   Are those fears supported by data and evidence?
    – The literature suggests NOT
Risk of cancer
 Bariatric surgeons fear Billroth 2 anastomosis
 Cancer surgeons choose Billroth 2
 Hundreds of thousands of people with Billroth 2.
    – If CA is such a big risk shouldn’t gastroenterologists be
      screening these people?
    – NO There is no recommendation to do endoscopic screening
      after Billroth 2

   The risk is LOW: endoscopy screening is not rewarding

    – Mayo clinic, 338 B2 patients, 25years FU, 5635 person-years.
      Only 2 cancers detected in >5000 pat-years of FU
        • Schafer et al Risk of gastric cancer after treatment of benign ulcer disease.
          N Engl J. Med 1983: Nov 17; 309

    – 1000 patients, 22-30 y FU, endoscopy, no CA in gastric
      remnant
        • Br J Surg 1983 Sep; 70 (9): 552-4 Risk of gastric cancer after B2 resection
          for duodenal ulcer. Fisher AB
Bile reflux
   Major problem with Mason Ito bypass
    – Anastomosis too close to oesophagus
 Risk with MGB is real
 Gastric tube has to be LONG
    – First staple firing well into gastric antrum
    – Anastomosis lies at level of the pylorus
    – RNY surgeons tend to make gastric pouch not long enough
 Can usually be treated medically
 Surgical intervention
                                                     Braun anastomosis
    – Braun anastomosis
    – Conversion to RNY (stenosis)
Marginal ulcer
 Marginal ulcer is the Achilles heel of all gastric bypass
  operations: it has been known since the beginning of GI surgery
 It is not just a problem for MGB.
 Risk factors: tobacco,nsaid,ischaemia, foreign body, alcohol,
  H pylori, poor diet
 Both RNY & MGB
    – Incidence: 0.6% to 12%
    – True incidence likely higher
    – 28% of marginal ulcers can be asymptomatic (Csendes prospective
      study)
 Bile makes no difference
 Marginal ulcer in RNY
    – 2282 patients
    – 122 (5%) marginal ulcers
    – 39 (32%) requiring surgery
        • Surg Obes Relat. Dis. 2009 May-Jun;5(3):317-22 Revisional operations
          for marginal ulcer after RNY gastric bypass Patel RA, Brolin RE
MGB experience at
                SPIRE Southampton Hospital

   Oct 2010 – Jan 2012
   2 cohorts of 52 patients: RNY vs. MGB
   Prospective data collection (NBSR and local database)
   Follow-up: standard 3 monthly
   Well matched
                                       RNY (N:52)       MGB (N:52)
                       Age             49.5 (31 – 63)   51.0 (24 – 71)
                       Gender M/F      22/30            23/ 29
                       Weight (Kg)     134.53 + 16.53   135.46 + 19.75


FU        rate at 12 months: 96% for both cohorts


02/02/13                                                             7
Patient characteristics
   ASA score
                         ASA                RNY      MGB
                              1                 5     7
                              2                27    18
                              3                19    25
                              4                 1     2
   Co-morbidity


                   Medical Morbidity                       RNY (N 52)       MGB (N 52)

                   T2DM                                    32 (5 Insulin)   30 (3 Insulin)
                   HT                                           23               33

                   Sleep apnoea                                 13               10

                   Asthma                                       15               18

                   Functional impairment                        41               48
                   (less than 3 flights of stairs)

                   OA (on meds)                                 15               25

                   GORD                                         11               15
02/02/13                                                                                     8
Results
   Mortality: 0% both groups
 Hospital stay: Med 2 days (MGB: 2-9 // RNY: 2-12)
 Early complications


                Complication               RNY (n 52)                   MGB (n 52)

             Intraperitoneal bleed   3 (1 RTT, 2 transfusion)

             GI endoluminal bleed     1 (RTT: endoscopy +
                                          laparoscopy)
              Anastomotic leak                                  1 (RTT: leak not identified)


            Aspiration pneumonia            1 (ARDS)

                 Pneumonia                                                1 (AB)

                Cardiac event                                                1

            Anastomotic stenosis          3 (dilatation)               3 (dilatation)
              Complication rate               15%                         11.5%



02/02/13                                                                                       9
Late complications MGB

   1 dysphagia / food intolerance: converted to normal anatomy at 6
    months

   1 marginal ulcer and ?bile reflux: converted to RNY (elsewhere) > 12
    months postop (heavy smoker)

   1 protein malnutrition: converted to proximal RNY > 12 months postop

   Reoperation rate: 5.7% (3/52)
     – Early experience
     – Learning curve
Effect on medical co-morbidity
Results at 12 months FU

             Medical       RNY     RNY          % improved   MGB     MGB (n 49)     % improved
            condition     preop   Last FU                    preop    Last FU

              T2DM         32         8            75%        30          7           76.7%

                HT         23        15           34.8%       33         20           39.4%

              Sleep        13         7            46%        10          4            60%
             apnoea
             Asthma        15        14           6.67%       18         11           38.9%
             Functional    41         1          97.57%       48          4           91.%
            impairment

                OA         15        12            20%        25         18            28%

              GORD         11        10            9%         15         11          26.67%
                                  (4 de novo)                         (4 de novo)




 02/02/13                                                                                     11
Weight loss results
                            Preop (mean + SD)   1 year (mean + SD)

     RNY weight Kg          136.01 ± 17.01      96.94 ± 16.55         p<0.01

     RNY BMI                48.84 ± 14.20       33.93 ± 4.93          p<0.01

     MGB weight Kg          134.62 ± 19.01      86.58 ± 14.7          p<0.01

     MGB BMI                48.40 ± 5.21        31.60 ± 4.68          p<0.01



                                                     RNY               MGB
     Preop (n 52)              Weight (Kg)           136.01 + 17.01    134.62 ± 19.01   NS

                               BMI operation         48.84 ± 14.20     48.40 + 5.21     NS

     1 year postop (n 50)      Weight                96.94 + 16.55     86.58 + 14.70    P<0.05

                               %EWL                  63.08 ± 18.56     75.69 + 15.32    P<0.05

                               BMI                   33.93 + 4.93      31.60 + 4.68


02/02/13                                                                                         12
Conclusions
 Mini   Gastric Bypass
  – Safe and easy procedure
  – Complications similar to RNY
  – Beware of “tricks” and “traps”
  – Medical benefits similar to RNY
  – Weight loss probably better than RNY
  – Valid alternative for RNY
Thank you

Más contenido relacionado

La actualidad más candente

Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Goto Pablo
 
Marginalulcergastricbypass4 blue
Marginalulcergastricbypass4 blueMarginalulcergastricbypass4 blue
Marginalulcergastricbypass4 blue
Dr. Robert Rutledge
 
Initial human experience with restrictive duodenal jejunal bypass liner for t...
Initial human experience with restrictive duodenal jejunal bypass liner for t...Initial human experience with restrictive duodenal jejunal bypass liner for t...
Initial human experience with restrictive duodenal jejunal bypass liner for t...
Ricardo Yanez
 
Weight loss surgery safe & effective
Weight loss surgery   safe & effectiveWeight loss surgery   safe & effective
Weight loss surgery safe & effective
foregutsurgeon
 
Restrictive Procedures in BMI > 50
Restrictive Procedures in BMI > 50Restrictive Procedures in BMI > 50
Restrictive Procedures in BMI > 50
George S. Ferzli
 

La actualidad más candente (19)

Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
 
The Mini-Gastric Bypass:Best Treatment Type 2 Diabetes Mellitus
The Mini-Gastric Bypass:Best Treatment Type 2 Diabetes MellitusThe Mini-Gastric Bypass:Best Treatment Type 2 Diabetes Mellitus
The Mini-Gastric Bypass:Best Treatment Type 2 Diabetes Mellitus
 
Bariatric surgery complications
Bariatric surgery complicationsBariatric surgery complications
Bariatric surgery complications
 
Aspectos paar decidir una conversión
Aspectos paar decidir una conversiónAspectos paar decidir una conversión
Aspectos paar decidir una conversión
 
Marginalulcergastricbypass4 blue
Marginalulcergastricbypass4 blueMarginalulcergastricbypass4 blue
Marginalulcergastricbypass4 blue
 
Trattamento chirurgico dell'esofago di Barrett - Gastrolearning®
Trattamento chirurgico dell'esofago di Barrett  -  Gastrolearning®Trattamento chirurgico dell'esofago di Barrett  -  Gastrolearning®
Trattamento chirurgico dell'esofago di Barrett - Gastrolearning®
 
kidney stones are common after bariatric surgery
kidney stones are common after bariatric surgerykidney stones are common after bariatric surgery
kidney stones are common after bariatric surgery
 
Mgb background intro
Mgb background introMgb background intro
Mgb background intro
 
Dall'esofago di Barrett all'adenocarcinoma: fisiopatologia e diagnosi - Gas...
Dall'esofago di Barrett all'adenocarcinoma: fisiopatologia e diagnosi  -  Gas...Dall'esofago di Barrett all'adenocarcinoma: fisiopatologia e diagnosi  -  Gas...
Dall'esofago di Barrett all'adenocarcinoma: fisiopatologia e diagnosi - Gas...
 
Kular Sleeve vs Mini-Gastric Bypass
Kular Sleeve vs Mini-Gastric BypassKular Sleeve vs Mini-Gastric Bypass
Kular Sleeve vs Mini-Gastric Bypass
 
Fear & Confusion about the Risk of Cancer after Bariatric Surgery
Fear & Confusion about the Risk of Cancer after Bariatric SurgeryFear & Confusion about the Risk of Cancer after Bariatric Surgery
Fear & Confusion about the Risk of Cancer after Bariatric Surgery
 
Critics of the Mini-Gastric Bypass were Wrong
Critics of the Mini-Gastric Bypass were WrongCritics of the Mini-Gastric Bypass were Wrong
Critics of the Mini-Gastric Bypass were Wrong
 
Outcomes of conversions in bariatric surgery mendoza 2011
Outcomes of conversions in bariatric surgery   mendoza 2011Outcomes of conversions in bariatric surgery   mendoza 2011
Outcomes of conversions in bariatric surgery mendoza 2011
 
Presentation; Marginal ulcer gastric bypass
Presentation; Marginal ulcer gastric bypassPresentation; Marginal ulcer gastric bypass
Presentation; Marginal ulcer gastric bypass
 
Initial human experience with restrictive duodenal jejunal bypass liner for t...
Initial human experience with restrictive duodenal jejunal bypass liner for t...Initial human experience with restrictive duodenal jejunal bypass liner for t...
Initial human experience with restrictive duodenal jejunal bypass liner for t...
 
Weight loss surgery safe & effective
Weight loss surgery   safe & effectiveWeight loss surgery   safe & effective
Weight loss surgery safe & effective
 
New Horizons in Gastric Surgery
New Horizons in Gastric SurgeryNew Horizons in Gastric Surgery
New Horizons in Gastric Surgery
 
Sleeve gastrectomy in patients with bmi
Sleeve gastrectomy in patients with bmiSleeve gastrectomy in patients with bmi
Sleeve gastrectomy in patients with bmi
 
Restrictive Procedures in BMI > 50
Restrictive Procedures in BMI > 50Restrictive Procedures in BMI > 50
Restrictive Procedures in BMI > 50
 

Destacado

Destacado (7)

RISK OF GASTRIC CANCER AFTER BILLROTH II IN THE
RISK OF GASTRIC CANCER AFTER BILLROTH II IN THE RISK OF GASTRIC CANCER AFTER BILLROTH II IN THE
RISK OF GASTRIC CANCER AFTER BILLROTH II IN THE
 
Prevention vs Treatment MGB Leaks v2
Prevention vs Treatment MGB Leaks v2Prevention vs Treatment MGB Leaks v2
Prevention vs Treatment MGB Leaks v2
 
Mini gastroplasty Dr Rutledge MG, MSG
Mini gastroplasty Dr Rutledge MG, MSGMini gastroplasty Dr Rutledge MG, MSG
Mini gastroplasty Dr Rutledge MG, MSG
 
Malabsorbtion post rny 3
Malabsorbtion post rny 3Malabsorbtion post rny 3
Malabsorbtion post rny 3
 
Malabsorbtion: Minimal after RNY; Major After MGB
Malabsorbtion: Minimal after RNY; Major After MGBMalabsorbtion: Minimal after RNY; Major After MGB
Malabsorbtion: Minimal after RNY; Major After MGB
 
Mgb Done Wrong v2
Mgb Done Wrong v2Mgb Done Wrong v2
Mgb Done Wrong v2
 
Absorb activities 2
Absorb activities 2Absorb activities 2
Absorb activities 2
 

Similar a Mini-Gastric Bypass in the United Kingdom

(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
Scintica Instrumentation
 
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
European School of Oncology
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD)
Dr Surendra Khosya
 
RUXOLINIB FOR MYELOFIBROSIS
RUXOLINIB FOR MYELOFIBROSISRUXOLINIB FOR MYELOFIBROSIS
RUXOLINIB FOR MYELOFIBROSIS
seayat1103
 
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...
Raj Kiran Medapalli
 
Mm final slides sort
Mm final slides sortMm final slides sort
Mm final slides sort
Ahad Lodhi
 
6 frederick
6 frederick6 frederick
6 frederick
spa718
 
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancerRare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
European School of Oncology
 

Similar a Mini-Gastric Bypass in the United Kingdom (20)

(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
 
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
 
2 10[1]
2 10[1]2 10[1]
2 10[1]
 
Radiotherapy in Breast Cancer: Current Issues
Radiotherapy in Breast Cancer: Current IssuesRadiotherapy in Breast Cancer: Current Issues
Radiotherapy in Breast Cancer: Current Issues
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD)
 
RUXOLINIB FOR MYELOFIBROSIS
RUXOLINIB FOR MYELOFIBROSISRUXOLINIB FOR MYELOFIBROSIS
RUXOLINIB FOR MYELOFIBROSIS
 
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
 
The Science of Rectal Microbicides Can We Make Them And Will People Use Them?
The Science of Rectal MicrobicidesCan We Make Them And Will People Use Them?The Science of Rectal MicrobicidesCan We Make Them And Will People Use Them?
The Science of Rectal Microbicides Can We Make Them And Will People Use Them?
 
Treatment of Platinum sensitive relapsed carcinoma ovary
Treatment of Platinum sensitive relapsed carcinoma ovaryTreatment of Platinum sensitive relapsed carcinoma ovary
Treatment of Platinum sensitive relapsed carcinoma ovary
 
Cáncer páncreas 2017
Cáncer páncreas 2017Cáncer páncreas 2017
Cáncer páncreas 2017
 
Hypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostateHypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostate
 
Effects of Simultaneous KP transplantation VS KD single in type 2 diabetics: ...
Effects of Simultaneous KP transplantation VS KD single in type 2 diabetics: ...Effects of Simultaneous KP transplantation VS KD single in type 2 diabetics: ...
Effects of Simultaneous KP transplantation VS KD single in type 2 diabetics: ...
 
Gist, gastrointestinal stromal tumor ppt sameer rastogi
Gist, gastrointestinal stromal tumor ppt sameer rastogiGist, gastrointestinal stromal tumor ppt sameer rastogi
Gist, gastrointestinal stromal tumor ppt sameer rastogi
 
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Asso...
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
Mm final slides sort
Mm final slides sortMm final slides sort
Mm final slides sort
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney Disease
 
6 frederick
6 frederick6 frederick
6 frederick
 
Contrast induced-Acute Kidney Injury
Contrast induced-Acute Kidney InjuryContrast induced-Acute Kidney Injury
Contrast induced-Acute Kidney Injury
 
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancerRare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
 

Más de Dr. Robert Rutledge

Más de Dr. Robert Rutledge (20)

Introducing the MGB2.pptx
Introducing the MGB2.pptxIntroducing the MGB2.pptx
Introducing the MGB2.pptx
 
The 4 MGB Things
The 4 MGB ThingsThe 4 MGB Things
The 4 MGB Things
 
Bp limb length microbiome
Bp limb length microbiomeBp limb length microbiome
Bp limb length microbiome
 
Understanding weight loss after bariatric surgery
Understanding weight loss after bariatric surgery Understanding weight loss after bariatric surgery
Understanding weight loss after bariatric surgery
 
Prevent & Treat Bile Reflux
Prevent & Treat Bile RefluxPrevent & Treat Bile Reflux
Prevent & Treat Bile Reflux
 
Prevent & Rx Bile Reflux
Prevent & Rx Bile RefluxPrevent & Rx Bile Reflux
Prevent & Rx Bile Reflux
 
MGB Tips and Ticks
MGB Tips and Ticks MGB Tips and Ticks
MGB Tips and Ticks
 
Understanding Weight Loss After Bariatric Surgery
Understanding Weight Loss After Bariatric SurgeryUnderstanding Weight Loss After Bariatric Surgery
Understanding Weight Loss After Bariatric Surgery
 
Complications & Revision of the MGB
Complications & Revision of the MGBComplications & Revision of the MGB
Complications & Revision of the MGB
 
SHORT AND LONG TERM COMPLICATIONS FOLLOWING THE MINI-GASTRIC BYPASS
SHORT AND LONG TERM COMPLICATIONS FOLLOWING THE MINI-GASTRIC BYPASS SHORT AND LONG TERM COMPLICATIONS FOLLOWING THE MINI-GASTRIC BYPASS
SHORT AND LONG TERM COMPLICATIONS FOLLOWING THE MINI-GASTRIC BYPASS
 
Common Complication, Errors & Misunderstandings in the MGB
Common Complication, Errors & Misunderstandings in the MGBCommon Complication, Errors & Misunderstandings in the MGB
Common Complication, Errors & Misunderstandings in the MGB
 
Fear of Gastric Cancer and the Billroth II
Fear of Gastric Cancer and the Billroth IIFear of Gastric Cancer and the Billroth II
Fear of Gastric Cancer and the Billroth II
 
Gastric cancer & Billroth II & the MGB
Gastric cancer & Billroth II & the MGBGastric cancer & Billroth II & the MGB
Gastric cancer & Billroth II & the MGB
 
Different & Better: the MGB-OAGB
Different & Better: the MGB-OAGBDifferent & Better: the MGB-OAGB
Different & Better: the MGB-OAGB
 
Why the band and sleeve fail
Why the band and sleeve failWhy the band and sleeve fail
Why the band and sleeve fail
 
MGB, the Billroth II as Ideal Bariatric Surgery Dubai
MGB, the Billroth II as Ideal Bariatric Surgery DubaiMGB, the Billroth II as Ideal Bariatric Surgery Dubai
MGB, the Billroth II as Ideal Bariatric Surgery Dubai
 
Mgb cancer & MGB Guidelines
Mgb cancer & MGB GuidelinesMgb cancer & MGB Guidelines
Mgb cancer & MGB Guidelines
 
Mgb billroth II Hx
Mgb billroth II HxMgb billroth II Hx
Mgb billroth II Hx
 
Mgb Review Corp 10 (2)
Mgb Review Corp 10 (2)Mgb Review Corp 10 (2)
Mgb Review Corp 10 (2)
 
Dr Rutledge, Mini-Gastric Bypass & Bilio-Pancreatic Limb Length,
Dr Rutledge, Mini-Gastric Bypass & Bilio-Pancreatic Limb Length, Dr Rutledge, Mini-Gastric Bypass & Bilio-Pancreatic Limb Length,
Dr Rutledge, Mini-Gastric Bypass & Bilio-Pancreatic Limb Length,
 

Último

1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 

Último (20)

microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptx
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptx
 

Mini-Gastric Bypass in the United Kingdom

  • 1. 4th Annual Scientific Meeting Jan 23-25, 2013 Glasgow Mini Gastric Bypass: initial experience SPIRE Hospital Southampton Department of Bariatric Surgery M Van den Bossche, I Bailey, J Kelly J Byrne, R Sutherland* 02/02/13 1
  • 2. Introduction in MGB  Dr Robert Rutledge – Pioneer – 15 year experience – 7000 cases – Excellent results – Long term FU Mini Gastric Bypass is a combination of •Collis plasty •Billroth 2
  • 3. Fears and Controversy  MGB not endorsed by ASMBS or ACS but MGB is clearly on the rise throughout the world.  Fears – Cancer – Bile reflux – Marginal ulcer  Are those fears supported by data and evidence? – The literature suggests NOT
  • 4. Risk of cancer  Bariatric surgeons fear Billroth 2 anastomosis  Cancer surgeons choose Billroth 2  Hundreds of thousands of people with Billroth 2. – If CA is such a big risk shouldn’t gastroenterologists be screening these people? – NO There is no recommendation to do endoscopic screening after Billroth 2  The risk is LOW: endoscopy screening is not rewarding – Mayo clinic, 338 B2 patients, 25years FU, 5635 person-years. Only 2 cancers detected in >5000 pat-years of FU • Schafer et al Risk of gastric cancer after treatment of benign ulcer disease. N Engl J. Med 1983: Nov 17; 309 – 1000 patients, 22-30 y FU, endoscopy, no CA in gastric remnant • Br J Surg 1983 Sep; 70 (9): 552-4 Risk of gastric cancer after B2 resection for duodenal ulcer. Fisher AB
  • 5. Bile reflux  Major problem with Mason Ito bypass – Anastomosis too close to oesophagus  Risk with MGB is real  Gastric tube has to be LONG – First staple firing well into gastric antrum – Anastomosis lies at level of the pylorus – RNY surgeons tend to make gastric pouch not long enough  Can usually be treated medically  Surgical intervention Braun anastomosis – Braun anastomosis – Conversion to RNY (stenosis)
  • 6. Marginal ulcer  Marginal ulcer is the Achilles heel of all gastric bypass operations: it has been known since the beginning of GI surgery  It is not just a problem for MGB.  Risk factors: tobacco,nsaid,ischaemia, foreign body, alcohol, H pylori, poor diet  Both RNY & MGB – Incidence: 0.6% to 12% – True incidence likely higher – 28% of marginal ulcers can be asymptomatic (Csendes prospective study)  Bile makes no difference  Marginal ulcer in RNY – 2282 patients – 122 (5%) marginal ulcers – 39 (32%) requiring surgery • Surg Obes Relat. Dis. 2009 May-Jun;5(3):317-22 Revisional operations for marginal ulcer after RNY gastric bypass Patel RA, Brolin RE
  • 7. MGB experience at SPIRE Southampton Hospital  Oct 2010 – Jan 2012  2 cohorts of 52 patients: RNY vs. MGB  Prospective data collection (NBSR and local database)  Follow-up: standard 3 monthly  Well matched RNY (N:52) MGB (N:52) Age 49.5 (31 – 63) 51.0 (24 – 71) Gender M/F 22/30 23/ 29 Weight (Kg) 134.53 + 16.53 135.46 + 19.75 FU rate at 12 months: 96% for both cohorts 02/02/13 7
  • 8. Patient characteristics  ASA score ASA RNY MGB 1 5 7 2 27 18 3 19 25 4 1 2  Co-morbidity Medical Morbidity RNY (N 52) MGB (N 52) T2DM 32 (5 Insulin) 30 (3 Insulin) HT 23 33 Sleep apnoea 13 10 Asthma 15 18 Functional impairment 41 48 (less than 3 flights of stairs) OA (on meds) 15 25 GORD 11 15 02/02/13 8
  • 9. Results  Mortality: 0% both groups  Hospital stay: Med 2 days (MGB: 2-9 // RNY: 2-12)  Early complications Complication RNY (n 52) MGB (n 52) Intraperitoneal bleed 3 (1 RTT, 2 transfusion) GI endoluminal bleed 1 (RTT: endoscopy + laparoscopy) Anastomotic leak 1 (RTT: leak not identified) Aspiration pneumonia 1 (ARDS) Pneumonia 1 (AB) Cardiac event 1 Anastomotic stenosis 3 (dilatation) 3 (dilatation) Complication rate 15% 11.5% 02/02/13 9
  • 10. Late complications MGB  1 dysphagia / food intolerance: converted to normal anatomy at 6 months  1 marginal ulcer and ?bile reflux: converted to RNY (elsewhere) > 12 months postop (heavy smoker)  1 protein malnutrition: converted to proximal RNY > 12 months postop  Reoperation rate: 5.7% (3/52) – Early experience – Learning curve
  • 11. Effect on medical co-morbidity Results at 12 months FU Medical RNY RNY % improved MGB MGB (n 49) % improved condition preop Last FU preop Last FU T2DM 32 8 75% 30 7 76.7% HT 23 15 34.8% 33 20 39.4% Sleep 13 7 46% 10 4 60% apnoea Asthma 15 14 6.67% 18 11 38.9% Functional 41 1 97.57% 48 4 91.% impairment OA 15 12 20% 25 18 28% GORD 11 10 9% 15 11 26.67% (4 de novo) (4 de novo) 02/02/13 11
  • 12. Weight loss results Preop (mean + SD) 1 year (mean + SD) RNY weight Kg 136.01 ± 17.01 96.94 ± 16.55 p<0.01 RNY BMI 48.84 ± 14.20 33.93 ± 4.93 p<0.01 MGB weight Kg 134.62 ± 19.01 86.58 ± 14.7 p<0.01 MGB BMI 48.40 ± 5.21 31.60 ± 4.68 p<0.01 RNY MGB Preop (n 52) Weight (Kg) 136.01 + 17.01 134.62 ± 19.01 NS BMI operation 48.84 ± 14.20 48.40 + 5.21 NS 1 year postop (n 50) Weight 96.94 + 16.55 86.58 + 14.70 P<0.05 %EWL 63.08 ± 18.56 75.69 + 15.32 P<0.05 BMI 33.93 + 4.93 31.60 + 4.68 02/02/13 12
  • 13. Conclusions  Mini Gastric Bypass – Safe and easy procedure – Complications similar to RNY – Beware of “tricks” and “traps” – Medical benefits similar to RNY – Weight loss probably better than RNY – Valid alternative for RNY

Notas del editor

  1. The Mini Gastric Bypass was conceived and pioneered by Dr Robert Rutledge some 15 years ago . Over 15 years he has carried out more than 7000 procedures with excellent resuts. His operation is nothing more than a combination of a very long Collis plasty and a Billroth 2 type gastro jejunal anastomosis. That type of anastomosis was first introduced by Theodore Billroth in 1885 and is still widely used today by cancer surgeons, trauma surgeons and general surgeons.
  2. It is true that untill this day the MGB has not been endorsed by the leadership of the big American societies. When introduced MGB received al lot of criticism and many surgeons feared this operation would be tainted by the same problems as happened to the Mason Ito gastric bypass, an operation that was discredited in the 80 ’s: increased risk of cancer, bile reflux symptoms and marginal or stomal ulcer. (insert picture of Mason Ito bypass)
  3. It would appear that bariatric surgeons fear the Billroth 2 looped anastomosis yet cancer surgeon use the Billroth 2 operation. Every year thousands of Billroth 2 operation are performed in the US. (16000 in 2007) Many papers have been published detailing the safety of Billroth 2 and proving that there is no increased risk of cancer after this type of surgery
  4. Bile reflux was a debilitating problem with the Mason Ito bypass. With MGB as with any operastion there are some tricks and also some traps. If the gastric pouch is too short and/or there is an anastomotic stenosis then there is a high risk of bile reflux. If the gastric pouch is long and the anastomosis is wide then there will be no reflux. (insert picture of Braun anastomosis and of Mason Ito bypass)
  5. Marginal ulcers can occur with any type of gastro-enteric anastomosis. Marginal ulcers are seen both in MGB and RNY. Smoking, NSAIDS, ischaemia at the anastomosis and H Pylori are all known to be risk factors. Csendes from Santiago showed that the incidence of stomal ulcer after RNY can be as high as 12%. Brolin reported an incidence of 5% after RNY with a re-operation rate of 32%
  6. To evaluate the MGB we decided to compare 2 cohorts of patients: one consisting of RNY’s and another of MGB’s All data were collected prospectively The follow-up was identical for both groups and the cohorts were well matched with regard to funding, age, gender and operative weight. Only 2 patients were lost to FU in each cohort 12 months after surgery.
  7. The MGB group contained a larger number ASA3 patients The co-morbidity was fairly similar in both groups.
  8. Mortality was 0 in both groups and the length of stay identical. There were complications in both groups.. We had 5 early and 3 late complications in the RNY group. Explain them….. There were 2 early and 4 late complications in the MGB group. Explain them….
  9. Both operations have beneficial effects on co-morbidities. While the 6 month data suggested that the MGB would have a significantly better effect on T2DM the 12 month data showed identical results. The functional improvement is impressive in both groups. The effect of both bypasses on pre-existing reflux symptoms is not as strong as one would have expected. In both groups 4 patients developed de novo symptoms requiring daily PPI’s
  10. After 12 months the RNY group have lost on average 40Kg and their BMI has dropped 15 points The MGB patients on the other hand have lost on average 48Kg and have dropped 17 BMI points When we compare both groups we see that the MGB patients achieve 75% loss of Excess Weight while the RNY group achieves significantly less at 63%
  11. In conclusion I would like to say that MGB appears to be a safe, simple and easy to perform procedure with complications similar to the RNY. Just like with any other procedure there are certain tricks and traps one has to be aware of. The effects on co-morbidity are similar to the RNY. We did see a better weight loss with the MGB group. Our data are identical to the literature on MGB and support the claim that MGB is a valid alternative for the RNY.….